| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 6,452 | 16,826 | ||
| Short-term investments | 19,836 | 17,882 | ||
| Prepaid expenses and other current assets | 2,914 | 2,637 | ||
| Total current assets | 29,202 | 37,345 | ||
| Property and equipment, net | 616 | 573 | ||
| Operating lease right-of-use assets | 481 | 507 | ||
| Intangible assets | 67,726 | 67,566 | ||
| Other assets | 11,874 | 11,219 | ||
| Total assets | 109,899 | 117,210 | ||
| Accounts payable | 3,403 | 1,759 | ||
| Accrued expenses and other current liabilities | 5,121 | 5,708 | ||
| Current portion of debt | 17,520 | - | ||
| Total current liabilities | 26,044 | 7,467 | ||
| Debt | 0 | 16,989 | ||
| Long-term operating lease liabilities | 359 | 387 | ||
| Long-term contingent consideration | 61,213 | 59,147 | ||
| Deferred tax liabilities | 5,593 | 5,595 | ||
| Warrant liabilities | 14,853 | 15,144 | ||
| Other long-term liabilities | 778 | 745 | ||
| Total liabilities | 108,840 | 105,474 | ||
| Common stock, 0.001 par value, 250,000,000 shares authorized, 54,494,965 and 44,001,643 issued and outstanding as of september 30, 2025 and december 31, 2024, respectively | 54 | 53 | ||
| Additional paid in capital | 415,705 | 413,078 | ||
| Accumulated other comprehensive income (loss) | 6,293 | 6,156 | ||
| Accumulated deficit | -420,993 | -407,551 | ||
| Total stockholders equity | 1,059 | 11,736 | ||
| Total liabilities and stockholders equity | 109,899 | 117,210 | ||
Quince Therapeutics, Inc. (QNCX)
Quince Therapeutics, Inc. (QNCX)